Fig. 3

Co-expression of IL-13Rα2 and EGFRvIII enhances glioma transformation. a Cell proliferation of Gli36.EGFRvIII and Gli36.IL-13Rα2/EGFRvIII. b The cell cycle profile was compared between Gli36.EGFRvIII and Gli36.IL-13Rα2/EGFRvIII using flow cytometry analysis. c Soft agar colony formation assay of the indicated cells was performed, including the non-transforming Gli36 cells as a negative control. d IL-13Rα2 silencing (as validated by immunoblot presented as an insert) significantly reduced the proliferation of Gli36.IL-13Rα2/EGFRvIII cells to a level similar to the Gli36.EGFRvIII cells. e In vitro migratory capacity of Gli36.EGFRvIII and Gli36.IL-13Rα2/EGFRvIII cells. f U87MG.EGFRvIII cells were transfected with non-specific siRNA (CTRL-RNAi) or IL-13Rα2 specific siRNA (IL-13Rα2-RNAi). Cell proliferation was determined with CCK-8 assay in U87.EGFRvIII. The percent proliferation was normalized to CTRL-RNAi day 1. g In vitro migratory capacity of control and IL-13Rα2-RNAi treated U87MG.EGFRvIII was determined. Percent of migrated cells was normalized to CTRL-RNAi. All data are represented as mean ± SEM. ANOVA with Tukey's multiple comparison tests *p < 0.05; ***p < 0.001; NS not significant. h Kaplan−Meier survival curves of mice bearing Gli36.EGFRvIII and Gli36.IL-13Rα2/EGFRvIII tumors *p < 0.0292